Table of contents
- Trial overview
- Who can join the study
- Treatments being compared
- Study phase and size
- Outcomes being measured
- What this means for patients
Trial overview
The available trial data show one interventional study, which means researchers assign participants to study treatments rather than just observing them.[1] This trial is a Phase 3 study in advanced lung cancer and is currently listed as authorised.[1]
The study title describes a comparison of front-line platinum doublet therapy with sotorasib versus pembrolizumab in people with PD-L1 negative, KRAS p.G12C positive advanced or metastatic non-small cell lung cancer.[1] Hydroxocobalamin is listed among the study interventions in the trial record.[1]
Who can join the study
The trial is designed for people with stage IV or advanced stage IIIB/C nonsquamous non-small cell lung cancer.[1] It also requires the tumor to be PD-L1 negative and KRAS p.G12C positive.[1]
These details matter because they define the exact patient group the researchers want to study.[1] In simple terms, the trial is focused on people with a specific advanced lung cancer type and a specific tumor test pattern.[1]
Treatments being compared
The trial record lists several drugs in the intervention section, including Hydroxocobalamin, dexamethasone, sotorasib, folic acid, carboplatin, pembrolizumab, and pemetrexed.[1] The brief summary says the study is comparing participants who receive sotorasib with chemotherapy versus pembrolizumab with chemotherapy.[1]
This means the main research question is which treatment approach works better for the study group.[1] The trial is not simply checking whether a single drug works in isolation; it is comparing treatment strategies in a real cancer setting.[1]
Study phase and size
This is a Phase 3 trial, which usually means a larger study that compares treatments and looks for strong evidence of benefit.[1] The planned enrollment is 721 participants.[1]
A larger sample helps researchers compare results more reliably across the treatment groups.[1] In this study, that size is important because the trial is measuring survival-related outcomes in a specific lung cancer population.[1]
Outcomes being measured
The main outcome is progression-free survival (PFS).[1] PFS is the time from randomization until the disease gets worse or the participant dies, whichever happens first.[1]
Disease progression will be judged by an independent review using RECIST v1.1, which is a standard way to measure tumor response in cancer trials.[1] The reviewers will not know which treatment the participant received, which helps reduce bias in reading the results.[1]
The brief summary also says the study will compare overall survival (OS), which is the time until death from any cause.[1] Together, PFS and OS help show whether one treatment strategy gives better control of the cancer and longer life.[1]
What this means for patients
For patients, this trial is mainly about finding the better first treatment strategy for a very specific group of advanced lung cancer.[1] The study looks at whether one treatment approach can delay cancer growth longer and improve survival.[1]
Because the trial record includes Hydroxocobalamin among the intervention drugs, it is part of the research data for this study record.[1] The source data do not give more detail about a separate Hydroxocobalamin-only trial, so the information here is limited to this lung cancer study record.[1]
